• 1
    Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 67387.
  • 2
    Jemal A,Murray T,Ward E,Samuels A,Tiwari RC,Ghafoor A,Feuer EJ,Thun MJ. Cancer statistics, 2005. CA Cancer. J Clin 2005; 55: 1030.
  • 3
    Walker MD,Green SB,Byar DP,Alexander E,Jr,Batzdorf U,Brooks WH,Hunt WE,MacCarty CS,Mahaley MS,Jr,Mealey J,Jr,Owens G,Ransohoff J,II, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 13239.
  • 4
    Burger PC,Kleihues P. Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer 1989; 63: 201423.
  • 5
    Daumas-Duport C,Scheithauer BW,Kelly PJ. A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin Proc 1987; 62: 43549.
  • 6
    Bashir R,Hochberg F,Oot R. Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 1988; 23: 2730.
  • 7
    Brem S,Cotran R,Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972; 48: 34756.
  • 8
    St Croix B,Rago C,Velculescu V,Traverso G,Romans KE,Montgomery E,Lal A,Riggins GJ,Lengauer C,Vogelstein B,Kinzler KW. Genes expressed in human tumor endothelium. Science 2000; 289: 1197202.
  • 9
    Varner JA,Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 1996; 87: 6987.
  • 10
    Brooks PC,Clark RA,Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 56971.
  • 11
    Abdollahi A,Griggs DW,Zieher H,Roth A,Lipson KE,Saffrich R,Grone H-J,Hallahan DE,Reisfeld RA,Debus J,Niethammer AG,Huber PE. Inhibition of αvβ3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 62709.
  • 12
    Xiong JP,Stehle T,Zhang R,Joachimiak A,Frech M,Goodman SL,Arnaout MA. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296: 1515.
  • 13
    Ding Q,Stewart J,Jr,Prince CW,Chang P-L,Trikha M,Han X,Grammer JR,Gladson CL. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 2002; 62: 533643.
  • 14
    MacDonald TJ,Shimada H,Tabrizi P,Zlokovic BV,Cheresh DA,Laug WE. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001; 48: 1517.
  • 15
    Cheresh DA,Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 1987; 262: 1770311.
  • 16
    Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Invest Drugs 2003; 4: 72231.
  • 17
    Westermark BPJ,Hugosson R. Determinants for the establishment of permanent tissue culture cell lines from human gliomas. Acta Pathol Microbiol Scand 1973; 81: 791805.
  • 18
    Jaffe EA,Nachman RL,Becker CG,Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 274556.
  • 19
    Nisato RE,Tille JC,Jonczyk A,Goodman SL,Pepper MS. Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003; 6: 10519.
  • 20
    Nakayama GR,Caton MC,Nova MP,Parandoosh Z. Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods 1997; 204: 2058.
  • 21
    Kim JH,Khil MS,Kolozsvary A,Gutierrez JA,Brown SL. Fractionated radiosurgery for 9L gliosarcoma in the rat brain. Int J Radiat Oncol Biol Phys 1999; 45: 103540.
  • 22
    Eskens FA,Dumez H,Hoekstra R,Perschl A,Brindley C,Bottcher S,Wynendaele W,Drevs J,Verweij J,van Oosterom AT. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003; 39: 91726.
  • 23
    DeArmond SJ,Stowring L,Amar A,Coopersmith P,Dougherty D,Spencer D,Mikkelsen T,Rosenblum M. Development of a non-selecting, non-perturbing method to study human brain tumor cell invasion in murine brain. J Neurooncol 1994; 20: 2734.
  • 24
    Aoki H,Kondo Y,Aldape K,Yamamoto A,Iwado E,Yokoyama T,Hollingsworth EF,Kobayashi R,Hess K,Shinojima N,Shingu T,Tamada Y, et al. Monitoring autophagy in glioblastoma with antibody against isoform b of human microtubule-associated protein 1 light Chain 3. Autophagy 2008; 4: 46775.
  • 25
    Fukushima Y,Ohnishi T,Arita N,Hayakawa T,Sekiguchi K. Integrin alpha3beta1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int J Cancer 1998; 76: 6372.
  • 26
    Castel S,Pagan R,Garcia R,Casaroli-Marano RP,Reina M,Mitjans F,Piulats J,Vilaro S. Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. Eur J Cell Biol 2000; 79: 50212.
  • 27
    Yatohgo T,Izumi M,Kashiwagi H,Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 1988; 13: 28192.
  • 28
    Pelloski CE,Lin E,Zhang L,Yung WKA,Colman H,Liu J-L,Woo SY,Heimberger AB,Suki D,Prados M,Chang S,Barker FG,III, et al. Prognostic associations of activated mitogen-activated protein kinaseand Akt pathways in glioblastoma. Clin Cancer Res 2006; 12: 393541.
  • 29
    Campbell KJ,Rocha S,Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004; 13: 85365.
  • 30
    Cordes N,Hansmeier B,Beinke C,Meineke V,van Beuningen D. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines 72. Br J Cancer 2003; 89: 212232.
  • 31
    MacDonald TJ,Taga T,Shimada H,Tabrizi P,Zlokovic BV,Cheresh DA,Laug WE. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha 31(v) integrin antagonist. Neurosurgery 2001; 48: 1517.
  • 32
    Campbell KJ,Perkins ND. Post-translational modification of RelA(p65) NF-kappaB. Biochem Soc Trans 2004; 32: 10879.
  • 33
    Jeong S-J,Pise-Masison CA,Radonovich MF,Park HU,Brady JN. A novel NF-κB pathway involving IKKβ and p65/RelA Ser-536 phosphorylation results in p53 inhibition in the absence of NF-κB transcriptional activity. J Biol Chem 2005; 280: 1032632.
  • 34
    Presta LG,Chen H,O'Connor SJ,Chisholm V,Meng YG,Krummen L,Winkler M,Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 45939.
  • 35
    Das R,Mahabeleshwar GH,Kundu GC. Osteopontin stimulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003; 278: 28593606.
  • 36
    Scatena M,Giachelli C. The αvβ3 integrin. NF-κB, osteoprotegerin endothelial cell survival pathway: potential role in angiogenesis. Trends Cardiovasc Med 2002; 12: 838.
  • 37
    Valerie K,Povirk LF. Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003; 22: 5792812.
  • 38
    Miller RA,Woodburn K,Fan Q,Renschler MF,Sessler JL,Koutcher JA. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 1999; 45: 9819.
  • 39
    Haubner R,Wester HJ,Weber WA,Mang C,Ziegler SI,Goodman SL,Senekowitsch SR,Kessler H,Schwaiger M. Noninvasive imaging of alpha(v)beta(3) integrin expression using F-18-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61: 17815.
  • 40
    Beer AJ,Haubner R,Goebel M,Luderschmidt S,Spilker ME,Wester HJ,Weber WA,Schwaiger M. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46: 133341.
  • 41
    Garkavtsev I,Kozin SV,Chernova O,Xu L,Winkler F,Brown E,Barnett GH,Jain RK. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004; 428: 32832.